Atosiban is named as an intervention in 3 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase EARLY_PHASE1. The sponsor with the most trials is University of Electronic Science and Technology of China (2). The most-studied condition is Infertility.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
The Effect of Oral Oxytocin and Atosiban on Social Attention
NCT07093060 · ClinicalTrials.gov ↗ · Healhty
|
Phase EARLY_PHASE1 | Recruiting | University of Electronic Science and Technology of China | China |
|
The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )
NCT07140237 · ClinicalTrials.gov ↗ · Healthy Adult Male
|
Phase EARLY_PHASE1 | Recruiting | University of Electronic Science and Technology of China | China |
|
Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions
NCT07185230 · ClinicalTrials.gov ↗ · Infertility
|
Not applicable | Recruiting | Northwest Women's and Children's Hospital, Xi'an, Shaanxi | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| University of Electronic Science and Technology of China | 2 |
| Northwest Women's and Children's Hospital, Xi'an, Shaanxi | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China register name Atosiban as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
University of Electronic Science and Technology of China (2) and Northwest Women's and Children's Hospital, Xi'an, Shaanxi (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Atosiban works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Atosiban works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Atosiban (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.